Hodgkin's lymphoma emerging radiation treatment techniques: Trade-offs between late radio-induced toxicities and secondary malignant neoplasms

Radiation Oncology

Volumn 8, Issue 1, 2013, Pages

  Cella, Laura ^a,b   Conson, Manuel ^b   Pressello, Maria Cristina ^c   Molinelli, Silvia ^d   Schneider, Uwe ^e   Donato, Vittorio ^c   Orecchia, Roberto ^f   Salvatore, Marco ^b   Pacelli, Roberto ^a,b  

^a CNR   (Italy)

^b UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^c SAN CAMILLO FORLANINI HOSPITAL   (Italy)

^d Centro Nazionale Adroterapia Oncologica CNAO   (Italy)

^e UNIVERSITY OF ZURICH   (Switzerland)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

Author keywords

Emerging radiotherapy techniques; Hodgkin's lymphoma; Radio induced toxicity; Second malignant neoplasm

Indexed keywords

ARTICLE; BREAST CANCER; CANCER RADIOTHERAPY; CANCER RISK; CELL POPULATION; CLINICAL ARTICLE; CONTROLLED STUDY; DOSIMETRY; FEMALE; FORWARD INTENSITY MODULATED RADIOTHERAPY; HODGKIN DISEASE; HUMAN; INTENSITY MODULATED RADIATION THERAPY; LUNG CANCER; PLANNING TARGET VOLUME; PROTON THERAPY; RADIATION DOSE; RADIATION INJURY; RISK REDUCTION; SUPRADIAPHRAGMATIC HODGKIN LYMPHOMA; THYROID CANCER; TOMOTHERAPY; TREATMENT PLANNING;

FEMALE; HODGKIN DISEASE; HUMANS; MODELS, THEORETICAL; NEOPLASMS, RADIATION-INDUCED; RADIOTHERAPY; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED;

EID: 84873026534     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-8-22     Document Type: Article

References (35)

1. Hodgson DC. Late effects in the era of modern therapy for Hodgkin lymphoma. Hematology Am Soc Hematol Educ Program 2011, 2011:323-329. 10.1182/asheducation-2011.1.323, 22160053.
2. Ng AK. Review of the cardiac long-term effects of therapy for Hodgkin lymphoma. Br J Haematol 2011, 154(1):23-31. 10.1111/j.1365-2141.2011.08713.x, 21539537.
3. Elkin EB, Klem ML, Gonzales AM. Characteristics and outcomes of breast cancer in women with and without a history of radiation for Hodgkin's lymphoma: a multi-institutional, matched cohort study. J Clin Oncol 2011, 29(18):2466-2473. 10.1200/JCO.2010.32.4079, 3138631, 21576642.
4. Hoppe BS, Flampouri S, Lynch J. Improving the therapeutic ratio in Hodgkin lymphoma through the use of proton therapy. Oncology (Williston Park) 2012, 26(5):456-459. 462-455.
5. Hoppe BS, Flampouri S, Su Z. Effective Dose Reduction to Cardiac Structures Using Protons Compared with 3DCRT and IMRT in Mediastinal Hodgkin Lymphoma. Int J Radiat Oncol Biol Phys 2012, 84(2):449-455. 10.1016/j.ijrobp.2011.12.034, 22386373.
6. Li J, Dabaja B, Reed V. Rationale for and preliminary results of proton beam therapy for mediastinal lymphoma. Int J Radiat Oncol Biol Phys 2011, 81(1):167-174. 10.1016/j.ijrobp.2010.05.007, 20643518.
7. Lu NN, Li YX, Wu RY. Dosimetric and Clinical Outcomes of Involved-Field Intensity-Modulated Radiotherapy After Chemotherapy for Early-Stage Hodgkin's Lymphoma With Mediastinal Involvement. Int J Radiat Oncol Biol Phys 2012, 84(1):210-216. 10.1016/j.ijrobp.2011.11.008, 22436783.
8. Vlachaki MT, Kumar S. Helical tomotherapy in the radiotherapy treatment of Hodgkin's disease - a feasibility study. J Appl Clin Med Phys 2010, 11(1):3042.
9. Nieder C, Schill S, Kneschaurek P. Comparison of three different mediastinal radiotherapy techniques in female patients: Impact on heart sparing and dose to the breasts. Radiother Oncol 2007, 82(3):301-307. 10.1016/j.radonc.2006.10.015, 17156873.
10. Fiandra C, Filippi AR, Catuzzo P. Different IMRT solutions vs. 3D-Conformal Radiotherapy in early stage Hodgkin's lymphoma: dosimetric comparison and clinical considerations. Radiat Oncol 2012, 7(1):186. 10.1186/1748-717X-7-186, 3502518, 23122028.
11. De Sanctis V, Bolzan C, D'Arienzo M. Intensity modulated radiotherapy in early stage Hodgkin lymphoma patients: is it better than three dimensional conformal radiotherapy?. Radiat Oncol 2012, 7:129. 10.1186/1748-717X-7-129, 3484070, 22857015.
12. Fox AM, Dosoretz AP, Mauch PM. Predictive factors for radiation pneumonitis in hodgkin lymphoma patients receiving combined-modality therapy. Int J Radiat Oncol Biol Phys 2012, 83(1):277-283. 10.1016/j.ijrobp.2011.05.078, 22019238.
13. Cella L, Conson M, Caterino M. Thyroid V30 Predicts Radiation-Induced Hypothyroidism in Patients Treated With Sequential Chemo-Radiotherapy for Hodgkin's Lymphoma. Int J Radiat Oncol Biol Phys 2012, 82(5):1802-1808. 10.1016/j.ijrobp.2010.09.054, 21514076.
14. Cella L, Liuzzi R, Conson M. Dosimetric predictors of asymptomatic heart valvular dysfunction following mediastinal irradiation for Hodgkin's lymphoma. Radiother Oncol 2011, 101(2):316-321. 10.1016/j.radonc.2011.08.040, 21925755.
15. Gagliardi G, Constine LS, Moiseenko V. Radiation dose-volume effects in the heart. Int J Radiat Oncol Biol Phys 2010, 76(3 Suppl):S77-85.
16. Hall EJ, Wuu CS. Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 2003, 56(1):83-88. 10.1016/S0360-3016(03)00073-7, 12694826.
17. Newhauser WD, Durante M. Assessing the risk of second malignancies after modern radiotherapy. Nat Rev Cancer 2011, 11(6):438-448. 10.1038/nrc3069, 21593785.
18. Berrington De Gonzalez A, Gilbert E, Curtis R. Second Solid Cancers After Radiation Therapy: A Systematic Review of the Epidemiologic Studies of the Radiation Dose-response Relationship. Int J Radiat Oncol Biol Phys 2012, Epub ahead of print.
19. Schneider U. Mechanistic model of radiation-induced cancer after fractionated radiotherapy using the linear-quadratic formula. Med Phys 2009, 36(4):1138-1143. 10.1118/1.3089792, 19472619.
20. Schneider U, Sumila M, Robotka J. Site-specific dose-response relationships for cancer induction from the combined Japanese A-bomb and Hodgkin cohorts for doses relevant to radiotherapy. Theor Biol Med Model 2011, 8:27. 10.1186/1742-4682-8-27, 3161945, 21791103.
21. Schneider U, Sumila M, Robotka J. Dose-response relationship for breast cancer induction at radiotherapy dose. Radiat Oncol 2011, 6:67. 10.1186/1748-717X-6-67, 3127785, 21651799.
22. Shuryak I, Hahnfeldt P, Hlatky L. A new view of radiation-induced cancer: integrating short- and long-term processes. Part I: approach. Radiat Environ Biophys 2009, 48(3):263-274. 10.1007/s00411-009-0230-3, 2714893, 19536557.
23. Shuryak I, Hahnfeldt P, Hlatky L. A new view of radiation-induced cancer: integrating short- and long-term processes. Part II: second cancer risk estimation. Radiation and environmental biophysics 2009, 48(3):275-286. 10.1007/s00411-009-0231-2, 2714894, 19499238.
24. Cella L, Liuzzi R, Magliulo M. Radiotherapy of large target volumes in Hodgkin's lymphoma: normal tissue sparing capability of forward IMRT versus conventional techniques. Radiat Oncol 2010, 5(1):33. 10.1186/1748-717X-5-33, 2881006, 20459790.
25. Feng M, Moran JM, Koelling T. Development and validation of a heart atlas to study cardiac exposure to radiation following treatment for breast cancer. Int J Radiat Oncol Biol Phys 2011, 79(1):10-18. 10.1016/j.ijrobp.2009.10.058, 2937165, 20421148.
26. Weber DC, Peguret N, Dipasquale G. Involved-node and involved-field volumetric modulated arc vs. fixed beam intensity-modulated radiotherapy for female patients with early-stage supra-diaphragmatic Hodgkin lymphoma: a comparative planning study. Int J Radiat Oncol Biol Phys 2009, 75(5):1578-1586. 10.1016/j.ijrobp.2009.05.012, 19596171.
27. D'Errico F, Luszik-Bhadra M, Nath R. Depth dose-equivalent and effective energies of photoneutrons generated by 6-18 MV X-ray beams for radiotherapy. Health Phys 2001, 80(1):4-11. 10.1097/00004032-200101000-00003, 11204115.
28. Schneider U, Agosteo S, Pedroni E. Secondary neutron dose during proton therapy using spot scanning. Int J Radiat Oncol Biol Phys 2002, 53(1):244-251. 10.1016/S0360-3016(01)02826-7, 12007965.
29. Engert A, Plutschow A, Eich HT. Reduced Treatment Intensity in Patients with Early-Stage Hodgkin's Lymphoma. N Engl J Med 2010, 363(7):640-652. 10.1056/NEJMoa1000067, 20818855.
30. Campbell BA, Hornby C, Cunninghame J. Minimising critical organ irradiation in limited stage Hodgkin lymphoma: a dosimetric study of the benefit of involved node radiotherapy. Ann Oncol 2012, 23(5):1259-1266. 10.1093/annonc/mdr439, 21980193.
31. ICRP Relative Biological Effectiveness, Radiation Weighting and Quality Factor". ICRP Publication 92. Ann. ICRP 33 (4) 2003, ICRP.
32. Edwards AA, Lloyd DC, Prosser JS. Chromosome aberrations induced in human lymphocytes by 8.7 MeV protons and 23.5 MeV helium-3 ions. Int J Radiat Biol Relat Stud Phys Chem Med 1986, 50(1):137-145. 10.1080/09553008614550511, 3013793.
33. NCRP The relative biological effectiveness of radiations of different quality. NCRP Report 104 1990, NCRP.
34. Foote RL, Stafford SL, Petersen IA. The clinical case for proton beam therapy. Radiat Oncol 2012, 7(1):174. 10.1186/1748-717X-7-174, 3549771, 23083010.
35. Schippers JM, Lomax AJ. Emerging technologies in proton therapy. Acta Oncol 2011, 50(6):838-850. 10.3109/0284186X.2011.582513, 21767183.